Related Experiment Videos
Rimonabant--a selective CB1 antagonist
Steven Thomas Boyd1, Brad Allen Fremming
1Department of Pharmacy Practice, School of Pharmacy and Health Professionals, Creighton University, Omaha, NE 67178-0401, USA. sboys@creighton.edu
The Annals of Pharmacotherapy
|March 10, 2005
Summary
Rimonabant, a selective cannabinoid receptor antagonist, shows promise for treating obesity and aiding smoking cessation. Further research is exploring its potential for metabolic syndrome and alcohol abuse.
Area of Science:
- Pharmacology and Therapeutics
- Endocannabinoid System Research
Background:
- Rimonabant is a novel selective antagonist of the cannabinoid receptor type 1 (CB1).
- The endocannabinoid system plays a role in appetite regulation and addiction pathways.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of rimonabant.
- To assess the potential therapeutic applications of rimonabant in obesity, smoking cessation, and metabolic syndrome.
Main Methods:
- A comprehensive literature search was conducted using MEDLINE (1966-November 2004) and bibliographies.
- Key search terms included obesity, smoking cessation, cannabinoid, and rimonabant.
- Relevant studies and review articles on rimonabant and the endocannabinoid system were included.
Main Results:
- Rimonabant demonstrated beneficial effects in preclinical and clinical studies for obesity and smoking cessation.
- Animal studies indicated reduced hunger, caloric intake, and body weight, with increased satiety.
- Human trials suggest efficacy in treating obesity and smoking cessation; nausea was the most common adverse effect, slightly exceeding placebo.
Conclusions:
- Rimonabant represents a new class of drugs: selective cannabinoid CB1 receptor antagonists.
- The drug showed potential for treating obesity and smoking cessation, with possible approval anticipated.
- Ongoing studies are investigating additional clinical uses, including metabolic syndrome and alcohol abuse.